Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arterial Vascular Engineering AVEI -- Ignore unavailable to you. Want to Upgrade?

To: gbh who wrote (245)	6/23/1998 6:52:00 PM
From: Platter	Read Replies (1) \| Respond to of 410

Maybe a buyout at $43.50

To: gbh who wrote (245)	6/25/1998 11:25:00 AM
From: gbh	Read Replies (1) \| Respond to of 410

AVE Signs Agreement With Columbia/HCA SANTA ROSA, Calif., June 25 /PRNewswire/ -- Arterial Vascular Engineering, Inc. (''AVE'') (Nasdaq: AVEI - news) today announced that it has entered into an agreement with the Columbia/HCA system of hospitals to supply AVE's coronary stent systems. ''Columbia/HCA hospitals have proven to be important customers and this National Account Agreement represents a significant milestone for us by defining our relationship with a sizable base of customers here in the United States,'' said Glenn Foley, AVE's Vice President of Sales in North America. ''We have seen strong physician acceptance of our technology in the United States, particularly since the recent release of our broad line of GFX(TM) coronary stent systems. We hope that this relationship with the Columbia/HCA hospital system will help to solidify the market share gains recently experienced.'' Headquartered in Santa Rosa, California, Arterial Vascular Engineering, Inc. is a leading provider of highly specialized stent and balloon angioplasty systems for less invasive interventional treatment of cardiovascular disease. AVE sells its stent and balloon angioplasty systems in more than 40 countries, including its coronary stent systems in the United States. Except for the historical information contained herein, this news release contains forward-looking statements that involve risks and uncertainties, including variations in the level of sales and earnings, the ability to manage growth effectively and to adequately increase personnel, the ability to cost-effectively establish, maintain or manage a suitable sales force, the effects of competition and pricing pressure, the rapid and significant technological change that characterizes the medical device industry and the ability to continue to respond to such technological change, and the ability to successfully introduce and achieve market acceptance for new products and continued demand for products generally, as well as the other risks detailed from time to time in documents filed by AVE with the SEC, including the report on Form 10-K for the year ended June 30,1997.